BlossomHill raises $168m IPO and wins FDA Fast Track for BH-30643
BlossomHill Therapeutics has completed an upsized $168.3 million initial public offering on Nasdaq and secured FDA Fast Track designation for BH-30643, its macrocyclic OMNI-EGFR inhibitor, in adult patients with advanced or metastatic EGFR C797S-positive non-small cell lung cancer who have progressed on a third-generation EGFR tyrosine kinase inhibitor. The San Diego company reported its second-quarter 2026 financial results alongside these corporate milestones, with a combined cash position it believes will fund operations into the second quarter of 2028.
The IPO, which closed in August 2026 and included partial exercise of the over-allotment option, raised gross proceeds of $168.3 million through the sale of approximately 10.5 million shares. Together with the $95.4 million in cash and equivalents held at 30 June 2026, that gives BlossomHill a substantial runway to pursue several near-term clinical inflection points. Second-quarter R&D expenses rose to $21.4 million from $12.5 million in the prior-year period, reflecting the cost of the ongoing SOLARA Phase 1/2 trial and IND-enabling work on the preclinical KRAS programme, BH-501284. The net loss for the quarter was $23.8 million.
Pipeline progress
The most clinically mature data in the release concern BH-30643. Presented at ASCO 2026 and updated at the IASLC World Conference on Lung Cancer, the SOLARA trial reported a 45% objective response rate and an 88% disease control rate in patients carrying the C797S resistance mutation, with or without concurrent T790M. These early figures, from a Phase 1 dose-escalation and backfill cohort rather than a pivotal readout, will need to be confirmed in a larger expansion cohort, but they support BlossomHill's case for accelerated approval discussions with the FDA. An end-of-Phase 1 meeting is anticipated before year-end, with first patient dosed in a pivotal Phase 2 trial targeted for the first quarter of 2027.
BH-30236, the company's macrocyclic CLK inhibitor being evaluated in relapsed or refractory AML and higher-risk myelodysplastic syndromes, presented initial Phase 1 data at the European Hematology Association congress showing early signs of anti-leukaemic activity as a monotherapy and in combination with venetoclax. The FDA has granted orphan drug designation to this programme. Updated Phase 1 data are expected in the first half of 2027.
Market context
The fourth-generation EGFR inhibitor space is attracting significant competitive attention. C797S-mediated resistance to osimertinib is a clinically validated but commercially underserved problem, and several companies are attempting to address it with allosteric, covalent and non-covalent macrocyclic approaches. BlossomHill's claim of selectivity over wild-type EGFR, brain penetrance, and activity across multiple resistance categories, including exon 20 insertions and atypical mutations, positions BH-30643 as a broad-spectrum candidate rather than a narrowly targeted rescue therapy. Whether that profile survives Phase 2 scrutiny, and how it will compare with programmes at larger peers in the space, remains the central investor question heading into 2027.
Founder and chief executive Jean Cui, whose prior career includes three FDA-approved oncology drugs, described the company as "well positioned to deliver important clinical and regulatory milestones over the coming quarters." BlossomHill's pipeline breadth across EGFR, CLK and KRAS gives it multiple shots on goal, though the KRAS programme remains preclinical with an IND submission not anticipated until the first quarter of 2027.